Press Releases | BioLineRx

Date	Title	Additional Formats
25 Nov 2024	BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value	PDF Version
21 Nov 2024	BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.	PDF Version
20 Nov 2024	BioLineRx to Report Third Quarter 2024 Results on November 25, 2024	PDF Version
05 Nov 2024	BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024	PDF Version
16 Oct 2024	BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide	PDF Version
17 Sep 2024	BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection	PDF Version
15 Aug 2024	BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates	PDF Version
08 Aug 2024	BioLineRx to Report Second Quarter 2024 Results on August 15, 2024	PDF Version
30 May 2024	BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)	PDF Version
28 May 2024	BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates	PDF Version
24 May 2024	BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting	PDF Version
22 May 2024	BioLineRx to Report First Quarter 2024 Results on May 28, 2024	PDF Version
17 May 2024	BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification	PDF Version
06 May 2024	BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024	PDF Version
17 Apr 2024	BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	PDF Version
10 Apr 2024	BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	PDF Version
01 Apr 2024	BioLineRx Announces $6 Million Registered Direct Offering	PDF Version
26 Mar 2024	BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	PDF Version
20 Mar 2024	BioLineRx to Report 2023 Annual Financial Results on March 26, 2024	PDF Version
04 Mar 2024	BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production	PDF Version
28 Feb 2024	BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)	PDF Version
16 Feb 2024	BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	PDF Version